This Day On The Street
Continue to site
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Soft Sales Zap Zimmer

Matria (MATR - Get Report), Zimmer (ZMH - Get Report) and Express Scripts (ESRX - Get Report) are all hurting after disappointing investors with their latest quarterly updates.

The big healthcare players saw their shares drop sharply Thursday after mixed performances on the earnings front, as the stock market swooned under rising fears tied to the debt markets.

Matria suffered the most pain, by far, as its stock weathered a double-digit percentage loss on reduced full-year guidance. The company, a specialist in disease management and wellness services, now expects to generate 2007 sales of just $355 million to $363 million -- well below the $374 million consensus estimate -- due to delays in some major contracts. The company lowered its full-year profit outlook by 14% to $1.42 to $1.55 a share, excluding stock-option expenses, as well.

After watching Matria set the bar too high in the past, Wall Street experts have seen their fears play out once again.

"Our biggest concern with Matria had been the projected earnings ramp in the back half of the year," Credit Suisse analyst Michael Glynn wrote on Thursday. "While this concern is reduced with the new guidance range, we are perplexed at how two new accounts could affect earnings so much.

"We are concerned there are other fundamental factors."

Therefore, Glynn remains on the sidelines with a neutral rating on Matria's stock. His firm has investment banking ties to the company.

Meanwhile, Matria claimed that it met expectations for the second quarter. However, the company's revenue of $88.1 million and its operating profits of 22 cents a share actually fell a bit shy of consensus estimates.

1 of 3

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
SYM TRADE IT LAST %CHG
ZMH $113.09 0.00%
ESRX $89.08 0.00%
MATR $6.00 0.00%
AAPL $129.62 0.00%
FB $79.34 0.00%

Markets

DOW 18,041.54 -190.48 -1.04%
S&P 500 2,104.20 -21.86 -1.03%
NASDAQ 5,032.7510 -56.6110 -1.11%

Partners Compare Online Brokers

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs